A5081800491- Acute Myeloid Leukemia Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood disorders and treatments
- Protein Degradation and Inhibitors
- Protease and Inhibitor Mechanisms
- Hematological disorders and diagnostics
- Cell death mechanisms and regulation
- Retinoids in leukemia and cellular processes
- Ubiquitin and proteasome pathways
- Infectious Aortic and Vascular Conditions
- Abdominal vascular conditions and treatments
- Pancreatitis Pathology and Treatment
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
Calvary Mater Newcastle Hospital
2019-2024
University of Newcastle Australia
2019-2024
Hunter Medical Research Institute
2019-2024
John Hunter Hospital
2019-2024
Central Coast Local Health District
2015
Mutations in the type III receptor tyrosine kinase FLT3 are frequent patients with acute myeloid leukemia (AML) and associated a poor prognosis. AML is characterized by overproduction of reactive oxygen species (ROS), which can induce cysteine oxidation redox-sensitive signaling proteins. Here, we sought to characterize specific pathways affected ROS assessing oncogenic primary samples. The or phosphorylation proteins that mediate growth proliferation was increased samples from patient...
In solid tumours, high expression of the glycolytic enzyme, α-enolase (ENO1), predicts for poor patient overall survival (OS), and circulating autoantibodies to ENO1 correlate positively with diagnosis negatively advanced disease. Although is one most highly expressed genes in acute myeloid leukaemia (AML), its potential role as a biomarker AML or precursor, myelodysplastic neoplasms (MDS), has not been investigated. A meta-analysis nine online datasets (n = 1419 patients) revealed that OS...
A 20-year-old man was admitted to a regional hospital with fevers, rigors, anorexia and left upper quadrant pain. It his fourth presentation the emergency department in preceding 10 days. On first two presentations, he had been sent home provisional diagnosis of renal colic. After review by general practitioner, undergone outpatient imaging that identified filling defects pulmonary arteries lower lobe, which were reported as being consistent emboli. In addition, hypodense splenic lesions...
Abstract FLT3-mutations are diagnosed in 25-30% of patients with acute myeloid leukemia (AML) and associated a poor prognosis. AML is the overproduction reactive oxygen species (ROS), which drives genomic instability through oxidation DNA bases, promoting clonal evolution, treatment resistance outcomes. ROS also important second messengers, triggering cysteine redox sensitive signaling proteins, however, specific pathways influenced by remain enigmatic. Here we have surveyed...
Abstract Introduction Variants of uncertain significance (VUS) are commonly reported in cancer with the widespread adoption diagnostic massive parallel sequencing. The rate reclassification VUS patients haematological malignancy is not known and we evaluated this retrospectively. We also investigated whether re‐evaluating 12–24 months or greater than 24 post‐initial classification was significant. Method A retrospective audit malignancies referred to Molecular Medicine Department at John...
ABSTRACT Alterations in the FMS-like tyrosine kinase 3 (FLT3) gene are most frequent driver mutations acute myeloid leukaemia (AML), linked to a high risk of relapse patients with internal tandem duplications (FLT3-ITD). Tyrosine inhibitors (TKIs) targeting FLT3 protein approved for clinical use, yet resistance often emerges. This is mainly seen following acquisition additional point domain (TKD), resulting double mutant FLT3-ITD/TKD, which sustains cell signalling and survival despite...
Acute myeloid leukemia (AML) is an aggressive and poor-prognosis blood cancer. Despite a low mutation burden compared to other cancers, AML heterogenous identifying robust therapeutic targets has been difficult. Genomic profiling greatly advanced our understanding of AML, revealed for therapy. However, only 50% patients have gene mutations that are currently druggable, relapse rates remain high. The addition proteomic emerging address these challenges.